The Application of Pre-clinical Animal Models to Optimise Nanoparticulate Drug Delivery for Hepatocellular Carcinoma

Author(s): Zhiwen Zhang, Liu Song, Jianfeng Guo*

Journal Name: Pharmaceutical Nanotechnology

Volume 6 , Issue 4 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Hepatocellular carcinoma (HCC) causes significant morbidity and high fatal outcome globally. Conventional therapeutic strategies for HCC have achieved significant improvements, but they have limitations and are far from ideal. Novel nanoparticulate drug delivery systems have recently presented great therapeutic potential for cancer therapeutics. Appropriate and accurate animal models (main mice) are the basis of preclinical and translational research of nanoparticulate drug formulations in HCC. This review will provide an overview of different animal models of HCC, with a particular emphasis on those applied to assess the clinical potential for drug nanopharmaceutics.

Keywords: Liver cancer, non-viral nanoparticles, translational research, hepatocellular carcinoma, high fatal outcome, conventional therapeutic.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 01 October, 2018
Page: [221 - 231]
Pages: 11
DOI: 10.2174/2211738506666181001121533

Article Metrics

PDF: 39